Methods for treating post traumatic stress disorder
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9376424-B2
Publication Date
2016-06-28
Expiration Date
Abstract
Compounds and compositions are described herein for treating post traumatic stress disorder.
Core Innovation
The invention relates to a method for treating a patient having post traumatic stress disorder by administering a compound of the formula or a pharmaceutically acceptable salt thereof. The compound family is described as selective vasopressin V1a antagonists, with compound structural formulae (I) and (II), and the disclosure links PTSD to altered vasopressin signaling and HPA axis disturbance.
The patent associates the invention with vasopressin receptor involvement including vasopressin V1a, vasopressin V1b, and vasopressin V2 receptors. It further relates PTSD to comorbid psychiatric disorders including major depression, anxiety, impulse/anger disorders, substance abuse, and intermittent explosive disorder.
Biological characterization is provided using human V1a receptor binding assays, including reported IC50 and Ki values for examples and selectivity against the V1b and V2 receptors. The disclosure includes CNS relevance support via preferential V1a activity and selectivity relative to other vasopressin receptor subtypes, including blood-brain barrier considerations.
Claims Coverage
One independent claim is identified: a method for treating post traumatic stress disorder by administering a compound of a specified formula or a pharmaceutically acceptable salt thereof. The claim set includes five inventive features, with refinements relating to psychiatric comorbidities, V1a receptor selectivity, and hydrochloride salt form.
Post traumatic stress disorder treatment by administering formula compound or pharmaceutically acceptable salt
A method for treating a patient having post traumatic stress disorder comprising administering a compound of the formula or a pharmaceutically acceptable salt thereof.
Comorbid psychiatric disorder categories defining the patient population
The patient has post traumatic stress disorder comorbid with one or more specified psychiatric disorder categories, including impulse control or anger disorders, general anxiety or related anxiety disorders, depression disorders, or combinations thereof.
Major depression comorbidity
The method is applied to a patient who has post traumatic stress disorder comorbid with major depression.
Selective vasopressin V1a antagonism
The compound is selective for the V1a receptor.
Hydrochloride salt form
The method is performed using a hydrochloride salt form.
The claims center on treating post traumatic stress disorder with a compound of a specified formula or a pharmaceutically acceptable salt, and further specify psychiatric comorbidities, V1a receptor selectivity, and hydrochloride salt form.
Stated Advantages
The compound exhibits blood-brain barrier penetration and predicted or claimed in vivo characteristics such as metabolic stability and safety.
Representative examples show high-affinity binding to human V1a and antagonist functional behavior.
Behavioral outcomes include modulation of predatory fear conditioning with fMRI hyperarousal blockade, and stress/aggression paradigms in which sexual motivation is preserved.
Additional assays described include social interaction and light:dark shuttle box, supporting efficacy claims for the V1a-targeting antagonist approach.
Documented Applications
Treatment of patients having post traumatic stress disorder.
Treatment of post traumatic stress disorder comorbid with impulse control or anger disorders, general anxiety or related anxiety disorders, depression disorders, or combinations thereof.
Treatment of post traumatic stress disorder comorbid with major depression.
Interested in licensing this patent?